Data / Federal grants / RFA-AI-28-017
Partnerships for Advancing Development of Diagnostics for Infectious Diseases
National Institutes of Health (Department of Health and Human Services) expects to post this opportunity around July 23, 2027, with applications due around October 14, 2027. It lists 10 awards expected, $10 million in total.
SpecStream is the live web data engine for teams and agents. It reads every open and forecast federal opportunity on Grants.gov each morning, and this page is that reading. Describe your organization once and the grants that fit arrive in your sheet, CRM, Slack or agent as they are posted.
Key facts
- Opportunity number
- RFA-AI-28-017
- Status
- Forecast
- Posted
- September 24, 2026
- Closes
- October 14, 2027
- Expected awards
- 10
- Total funding
- $10,000,000
- Cost sharing
- Not required
- Funding instrument
- Cooperative Agreement
- Category
- Health
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Contact
- Division of Microbiology and Infectious Diseases (DMID) Diagnostics Partnerships · [email protected] · Please contact via email.
Who can apply
- Independent school districts
- Native American tribal organizations (other than Federally recognized tribal governments)
- Small businesses
- City or township governments
- Special district governments
- Public housing authorities/Indian housing authorities
- State governments
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Native American tribal governments (Federally recognized)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- County governments
- Private institutions of higher education
- Public and State controlled institutions of higher education
- For profit organizations other than small businesses
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
What the agency says
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting partnerships between academic (or small business) investigators and one or more industrial partner(s) for translational development of a diagnostic test that has demonstrated proof-of-concept. Novel diagnostics are needed to implement treatment strategies, evaluate vaccines and identify infectious disease outbreaks, but too often, early diagnostic breakthroughs are not being translated into successful commercial products. Investigators often develop promising diagnostics but then face barriers when navigating the process towards commercialization. The goal is to align investigators with experienced industry partners early in the development process, to enable early de-risking and ensure that the end-product will be fit for purpose. A science advisory board together with NIAID oversight will help maintain the focus of projects. Annual meetings and workshops will foster collaborations and knowledge exchange with biotech/industry developers, and other investigators in the early diagnostic space. This partnership concept aligns with NIH’s mission to support the translation of the most promising diagnostic technologies to better treat and prevent infectious diseases. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Other open grants from the Department of Health and Human Services
| Opportunity | Status | Closes | Award ceiling | Total funding | Record |
|---|---|---|---|---|---|
| Long-term health outcomes of people living with spina bifida CDC-RFA-DD-26-0222 | Open | Oct 26 | $300,000 | $3,000,000 | grants.gov |
| GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed) RFA-HG-27-011 | Open | Oct 30 | $1,250,000 | $2,000,000 | grants.gov |
| GREGoRi Innovation Projects (U01 Clinical Trial Optional) RFA-HG-27-013 | Open | Oct 30 | $500,000 | $7,500,000 | grants.gov |
| GREGoRi Technology Integration Center (U01, Clinical Trials Optional) RFA-HG-27-012 | Open | Oct 30 | $2,250,000 | $3,000,000 | grants.gov |
| HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required) PAR-27-045 | Open | Oct 30 | grants.gov | ||
| Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) PAR-24-280 | Open | Nov 2 | grants.gov |
All grants open to Independent school districts · All grants open to Tribal organizations · All grants open to Small businesses · Everything closing in October 2027
Read from the Grants.gov API, last updated 2026-10-23. The agency's notice on Grants.gov is the official record; check it before you apply.